These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 34058412)
21. A gut solution for hepatic encephalopathy. Vaquero J; Bañares R Hepatology; 2015 Jun; 61(6):2107-009. PubMed ID: 25777043 [No Abstract] [Full Text] [Related]
22. Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy. Sharma P; Sharma BC; Sarin SK Eur J Gastroenterol Hepatol; 2010 May; 22(5):526-31. PubMed ID: 20009938 [TBL] [Abstract][Full Text] [Related]
23. Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical Outcomes. Rahimi RS; Brown KA; Flamm SL; Brown RS Am J Med; 2021 Nov; 134(11):1330-1338. PubMed ID: 34242619 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of lactulose in the prophylaxis of hepatic encephalopathy in cirrhotic patients presenting gastrointestinal bleeding. Aires FT; Ramos PT; Bernardo WM Rev Assoc Med Bras (1992); 2016; 62(3):243-7. PubMed ID: 27310548 [TBL] [Abstract][Full Text] [Related]
25. [Not Available]. Sauerbruch T Dtsch Med Wochenschr; 2016 Aug; 141(17):1214. PubMed ID: 27557064 [No Abstract] [Full Text] [Related]
26. Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: A multicenter, randomized controlled trial. Wang JY; Bajaj JS; Wang JB; Shang J; Zhou XM; Guo XL; Zhu X; Meng LN; Jiang HX; Mi YQ; Xu JM; Yang JH; Wang BS; Zhang NP J Dig Dis; 2019 Oct; 20(10):547-556. PubMed ID: 31448533 [TBL] [Abstract][Full Text] [Related]
27. Lactulose a day keeps encephalopathy at bay. Klinken E; MacQuillan G J Gastroenterol Hepatol; 2011 Jun; 26(6):939-40. PubMed ID: 21564285 [No Abstract] [Full Text] [Related]
28. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Poo JL; Góngora J; Sánchez-Avila F; Aguilar-Castillo S; García-Ramos G; Fernández-Zertuche M; Rodríguez-Fragoso L; Uribe M Ann Hepatol; 2006; 5(4):281-8. PubMed ID: 17151582 [TBL] [Abstract][Full Text] [Related]
29. [Overt hepatic encephalopathy: extension of therapeutic armamentarium by old friends?]. Nguyen-Tat M; Schattenberg JM Z Gastroenterol; 2015 Jul; 53(7):724-5. PubMed ID: 26167699 [No Abstract] [Full Text] [Related]
31. Rifaximin for episodic, overt hepatic encephalopathy: the data are catching up to clinical practice, but questions remain. Congly SE; Leise MD Am J Gastroenterol; 2014 Apr; 109(4):598. PubMed ID: 24698864 [No Abstract] [Full Text] [Related]
33. Polyethylene Glycol Versus Lactulose for Hepatic Encephalopathy: Do We Have a Clear Winner? Giri S J Clin Gastroenterol; 2022 Feb; 56(2):192. PubMed ID: 35104256 [No Abstract] [Full Text] [Related]
34. Polyethylene glycol for hepatic encephalopathy: a new solution to purge an old problem? Doran AE; Shah NL JAMA Intern Med; 2014 Nov; 174(11):1734-5. PubMed ID: 25244573 [No Abstract] [Full Text] [Related]
35. What improves minimal hepatic encephalopathy: probiotic yogurt, protein restriction or nonabsorbable disaccharides? Alfawaz HA; Aljumah AA Saudi J Gastroenterol; 2012; 18(3):153-4. PubMed ID: 22626793 [No Abstract] [Full Text] [Related]
36. Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort. Bajaj JS; O'Leary JG; Tandon P; Wong F; Kamath PS; Biggins SW; Garcia-Tsao G; Lai J; Fallon MB; Thuluvath PJ; Vargas HE; Maliakkal B; Subramanian RM; Thacker LR; Reddy KR Aliment Pharmacol Ther; 2019 Jun; 49(12):1518-1527. PubMed ID: 31032966 [TBL] [Abstract][Full Text] [Related]
37. Response to Congly and Leise. Praveen S; Chander SB Am J Gastroenterol; 2014 Apr; 109(4):598-9. PubMed ID: 24698865 [No Abstract] [Full Text] [Related]
38. Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose. Sharma P; Agrawal A; Sharma BC; Sarin SK J Gastroenterol Hepatol; 2011 Jun; 26(6):996-1003. PubMed ID: 21129028 [TBL] [Abstract][Full Text] [Related]
39. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis. Irimia R; Trifan A Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882 [TBL] [Abstract][Full Text] [Related]
40. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy. Ahire K; Sonawale A J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]